Biotechpharma UAB expanding productionLituanian CDMO Biotechpharma UAB has invested €50m in order to expand its production capacity to 5000 litres. more ➔
Kiadis Pharma NV to acquire CytoSen Therapeutics, Inc.Kiadis Pharma NV has entered a definitive agreement to acquire US-based CytoSen Therapeutics, Inc. in order to create a leader in cell-based cancer immunotherapy. more ➔
Treating diabetes by mimicking gut bacteria effectsResearchers at University of Glasgow report that modulation of a specific GPCR results in health benefits normally mediated by a healthy gut microbiome. more ➔
Immunic lists at NasdaqChronic inflammatory disease company Immunic Therapeutics starts Nasdaq-trade following merger with Vital Therapies. more ➔
Preventing virus infections in newborns Scientists from Belgium and the US have found a way to prevent the devasting consequences of herpes infections for newborn babies. more ➔
Evotec and Indivumed join forces in CRCEvotec SE and Indivumed GmbH have entered into a drug R&D collaboration aimed at developing first-in-class colorectal cancer treatments. more ➔
Theranexus colloborates with AI expert DylissLyon-based neurology specialist Theranexus SA has launched a new bioinformatics partnership with systems biology data analysts from Dyliss (Dynamics, Logics and Inference for biological Systems and … more ➔
uniQure Receives FDA Fast Track Designation for AMT-130Following the FDA granted AMT-130 fast track designation, uniQure NV announced it will start Phase I/II testing of the Huntington’s Disease gene therapy in Q2/2019. more ➔
Sanofi ends option phase of rare disease partnership with AlnylamSanofi and Alnylam have agreed to end the research and option phase of the companies’ RNAi therapeutics alliance in rare genetic diseases. more ➔
Medigene AG in potential €1bn licence and R&D dealRoivant Sciences and Sinovant Sciences have launched newco Cytovant Sciences, which licenced two T cell-based cancer immune therapies and two development programmes from Medigene AG for commercialisation … more ➔
